Bifidobacterium breve – BR03 (DSM 16604)

Tabella dei contenuti

Clinical indications

atopic dermatitis, constipation, Cystitis, ibs, immune stimulation, intestinal transit, kidney stones, mood and sleep quality, sport performance

Area of use

Gastroenterology strain | Constipation – Antipathogenic activity

Characteristics

DAILY DOSAGE IN CLINICAL STUDY
1) 10 billion CFU (uncoated)
2) 5 billion CFU uncoated and 1 billion cells microencapsulated


FUNCTIONALITY
Constipation • Intestinal transit • Anti-inflammatory • Reduction of gastro-intestinal discomfort • Inhibition of pathogenic E. coli

Scientific support

Human clinical trials
1) Del Piano M. et al. The use of probiotics in the treatment of constipation in the elderly CIBUS, 2005; 1(1):23-30.
2) Del Piano M. et al. Evaluation of the intestinal colonization by microencapsulated probiotic bacteria in comparison with the same uncoated strains. J Clin Gastroenterol. 2010; 44 Suppl 1:S42-6.

In vitro studies
a) Mogna L. et al. Assessment of the In Vitro Inhibitory Activity of Specific Probiotic Bacteria Against Different Escherichia coli strains. J Clin Gastroenterol. 2012;46 Suppl.S29-32.
b) Nicola S. et al. Interaction between probiotics and human immune cells: the prospective anti-inflammatory activity of Bifidobacterium breve BR03. AgroFOOD, 2010; 21(2):S44-47.
c) Del Piano M. et al. In Vitro Sensitivity of Probiotics to Human Pancreatic Juice. J Clin Gastroenterol. Vol 42, Suppl. 3, Part 2, Sept. 2008. (DSM 20074 was re-deposited as 22106).


Gastroenterology blend | Baby colic

  • Bifidobacterium breve – BR03 (DSM 16604)
  • Bifidobacterium breve – B632 (DSM 24706)

Characteristics

DAILY DOSAGE IN CLINICAL STUDY
1,3) 100 million CFU + 100 million CFU
2) 1 billion CFU + 1 billion CFU


FUNCTIONALITY
Gaseous colic • Prevention of gastrointestinal symptoms • Rebalance of the intestinal microbiota in children and in infants • Inhibition of Enterobacteriaceae and of other coliforms isolated from colicky infants

Scientific support

Human clinical trials
1) Bona G. et al. The association of BR03 and B632 is effective to prevent colics in bottle-fed infants: a pilot, controlled, randomized and double blind study. Published in J Clin Gastroenterol, 2016.
2) Giglione E. et al. The Association of Bifidobacterium breve BR03 and B632 is Effective to Prevent Colics in Bottle-fed Infants: A Pilot, Controlled, Randomized, and Double-Blind Study. J Clin Gastroenterol. 2016 Nov/Dec; 50 Suppl. 2, Proceedings from the 8th Probiotics, Prebiotics & New Foods for Microbiota and Human Health meeting held in Rome, Italy on September 13-15, 2015:S164-S167.
3) Aloisio I. et al. Three-Month Feeding Integration With Bifidobacterium Strains Prevents Gastrointestinal Symptoms in Healthy Newborns. Frontiers in Nutrition, May 2018, art. 39.
4) Mogna L. et al. Capability of the Two Microorganisms Bifidobacterium breve B632 and Bifidobacterium breve BR03 to Colonize the Intestinal Microbiota of Children J Clin Gastroenterol, 2014. Suppl. 1, November/
December, Vol. 48.

See next page for other studies on this combination in celiac disease

In vitro studies
a) Simone M. et al. The Probiotic Bifidobacterium breve B632 Inhibited the Growth of Enterobacteriaceae within Colicky Infant Microbiota Cultures. BioMed Research International 1- 6, 2014.
b) Aloisio I. et al. Characterization of Bifidobacterium spp. strains for the treatment of enteric disorders in newborns. Appl Microbiol Biotechnol 2012, 96:1561–1576.
c) Nicola S. et al. Interaction between probiotics and human immune cells: the prospective anti-inflammatory activity of Bifidobacterium breve BR03. AgroFOOD, 2010; 21(2):S44-47.
d) Mogna L. et al. Assessment of the In Vitro Inhibitory Activity of Specific Probiotic Bacteria Against Different Escherichia coli strains. J Clin Gastroenterol. 2012; 46 Suppl.S29-32.
e) Del Piano M. et al. In Vitro Sensitivity of Probiotics to Human Pancreatic Juice. J Clin Gastroenterol. Vol 42, Suppl. 3, Part 2, Sept. 2008. (DSM 20074 was re-deposited as 22106).


Gastroenterology blend | Celiac disease

  • Bifidobacterium breve – BR03 (DSM 16604)
  • Bifidobacterium breve – B632 (DSM 24706)

Characteristics

DAILY DOSAGE IN CLINICAL STUDY
1,3) 100 million CFU + 100 million CFU
2) 1 billion CFU + 1 billion CFU


FUNCTIONALITY
Decrease inflammation in celiac disease

Scientific support

Human clinical trials
1) Mogna L. et al. Capability of the two microorganisms B632 and BR03 to colonize the intestinal microbiota of children. J Clin Gastroenterol. 2014; 48 Suppl:S37-39.
2) Klemenak M. et al. Administration of decreases the production of TNF-α in children with celiac disease. Dig Dis Sci (2015).
3) Quagliariello A. et al. Effect of Bifidobacterium breve on the Intestinal Microbiota of Coeliac Children on a Gluten Free Diet: A Pilot Study. Nutrients. 2016 Oct 22;8(10). pii:E660.
4) Primec M. et al. Clinical intervention using Bifidobacterium strains in celiac disease children reveals novel microbial modulators of TNF-a and short-chain fatty acids. Clinical Nutrition 2018, 1-9.


Gastroenterology blend | IBS – Constipation

  • Lactobacillus plantarum – LP01 (LMG P-21021)
  • Bifidobacterium breve – BR03 (DSM 16604)

Characteristics

DAILY DOSAGE IN CLINICAL STUDY
1) 5 billion CFU + 5 billion CFU
2,4) 5 billion CFU / strain (uncoated form) vs. 1 billion cells/strain (microencapsulated form)
3) 2.5 billion CFU + 2.5 billion CFU • 5) 10 billion CFU


FUNCTIONALITY
IBS • Constipation • Intestinal transit • Reduction of gastro-intestinal discomfort • Reduction of inflammation • Inhibition of E. coli, including toxinogenic O157:H7

Scientific support

Human clinical trials
1) Saggioro A. Probiotics in the treatment of Irritable Bowel Syndrome. J Clin Gastroenterol, 2004; 38(8): S104-106.
2) Del Piano M. et al. Evaluation of the intestinal colonization by microencapsulated probiotic bacteria in comparison with the same uncoated strains. J Clin Gastroenterol. 2010; 44 Suppl 1:S42-6.
3) Del Piano et al. The use of probiotics in healthy volunteers with evacuation disorders and hard stools. A double blind, randomized, placebo-con- trolled study. Journal of Clinical Gastroenterology, 2010; 44(8): S30-34.
4) Dimidi E. et al. The effect of probiotics on functional constipation in adults: a systematic review and meta-analysis of randomized controlled trials. Am J Clin Nutr 2014;100:1075–84.
5) Del Piano M. et al. The use of probiotics in the treatment of constipation in the elderly (BL03, LP01, BS01, LR05, BA02 and BR03 seperately). CIBUS, 2005; 1(1):23-30


Dermatology blend | Atopic dermatitis

  • Lactobacillus salivarius – LS01 (DSM 22775)
  • Bifidobacterium breve – BR03 (DSM 16604)

Characteristics

DAILY DOSAGE IN CLINICAL STUDY
1,3,4) 2 billion CFU + 2 billion CFU LS01 + BR03
2) 1 billion CFU + 1 billion CFU


FUNCTIONALITY
Reduce frequency, duration and intensity of Atopic Dermatitis symptoms • Improvement of the Quality of Life in subjects with Atopic Dermatitis (AD) • Rosacea • Chronic urticaria • Skin health

Scientific support

Human clinical trials
1) Iemoli E. et al. Probiotics reduce gut microbial translocation and improve adult atopic dermatitis. J Clin Gastroenterol. 2012; 46 Suppl:S33-40.
2) Licari A. et al. Efficacia clinica di Lactobacillus salivarius LS01 e Bifidobacterium breve BR03 in pazienti pediatrici affetti da dermatite atopica. Il medico pediatra 2016;38-42.
3) Nettis E. et al. Probiotics and refractory chronic spontaneous urticaria. Eur Ann Allergy Immunol 2016, Vol 48, N 5, 182-187.
4) Fortuna M. C. et al. A case of Scalp Rosacea treated with low dose doxycycline and probiotic therapy and literature review on therapeutic options. Dermatologic Therapy ISSN 1396-0296; DOI:10.1111/12355.

In vitro study
a) Deidda F. et al. New Approach in Acne Therapy: A Specific Bacteriocin Activity and a Targeted Anti IL-8 Property in Just 1 Probiotic Strain, the L. salivarius LS03. J Clin Gastroenterol. 2018 May 18.
b) Drago L. Immunomodulatory Effects of Lactobacillus salivarius LS01 and Bifidobacterium breve BR03, alone and in combination, on Peripheral Blood Mononuclear Cells of Allergic Asthmatics. Allergy Asthma Immunol Res. 2015 July; 7(4):409-413.


Dietetics strain | Weight management

Characteristics

FUNCTIONALITY
Restoration of a better dietary ω-6/ω-3 balance • Conjugated linoleic acids (CLA) production • Prospective use in the treatment of obesity

Scientific support

Internal data available upon request


Dietetics blend | Sport performance

  • Bifidobacterium breve – BR03 (DSM 16604)
  • Streptococcus thermophilus – FP4 (DSM 18616)

Characteristics

DAILY DOSAGE IN CLINICAL STUDY
1) 5 billion CFU + 5 billion CFU


FUNCTIONALITY
Immune response improving • Performance enhancing

Scientific support

Human clinical trials
Jäger R. et al. Probiotic Streptococcus thermophilus FP4 and Bifidobacterium breve BR03 Supplementation Attenuates Performance and Range-of-Motion Decrements Following Muscle Damaging Exercise. Nutrients. 2016 Oct 14;8(10). pii: E642.
Reviews
Pane M. et al. Gut Microbiota, Probiotics, and Sport: From Clinical Evidence to Agonistic Performance. J Clin Gastroenterol, 2018;52:S46-S49.

In vitro studies
a) Nicola S. et al. Interaction between probiotics and human immune cells: the prospective anti-inflammatory activity of Bifidobacterium breve BR03. AgroFOOD, 2010; 21(2):S44-47.
b) Mogna L. et al. Assessment of the in vitro inhibitory activity of specific probiotic bacteria against different Escherichia coli strains (LP01, LP02, LR04, LR06, LPS01, LDD01, BR03, B632). J Clin Gastroenterol. 2012; 46 Suppl:S29-32.

+ Internal data available upon request on CLA production and protection of gut epithelial barrier with BR03 (TEER)


Urology strain | Antipathogenic activity

Characteristics

FUNCTIONALITY
Cystitis • Inhibition of E. coli

Scientific support

In vitro studies
Mogna L. et al. Assessment of the in vitro inhibitory activity of specific probiotic bacteria against different Escherichia coli strains (LP01, LP02, LR04, LR06, LPS01, LDD01, BR03, B632). J Clin Gastroenterol. 2012; 46 Suppl:S29-32.


Urology strain | Kidney stones

Characteristics

FUNCTIONALITY
Oxalate degradation • Reduction of intestinal inflammation • Potential reduction of kidney stones incidence

Scientific support

In vitro studies
Mogna L. et al. Screening of different probiotic strains for their in vitro ability to metabolise oxalates: any prospective use in humans? (LPC09, LA02, LP01, LRE02, BR03, BL03) J Clin Gastroenterol. 2014; 48 Suppl:S91-95.


Gut-brain blend | Encephalomyelitis – Chronic fatigue

  • Lactobacillus rhamnosus – GG (ATCC 53103)
  • Bifidobacterium animalis subsp. lactis – BS01 (LMG P-21384)
  • Bifidobacterium breve – BR03 (DSM 16604)
  • Bifidobacterium longum – BL03 (DSM 16603)

Characteristics

DAILY DOSAGE IN CLINICAL STUDY
GG 25 billion CFU + BS01 15 billion CFU + BR03 5 billion CFU + BL03 5 billion CFU


FUNCTIONALITY
Sleep improvement and cognitive symptoms improvement in patients with encephalomyelitis/chronic fatigue syndrome

Scientific support

Human clinical trial
Wallis A. et al. Open-label pilot for treatment targeting gut dysbiosis in myalgic encephalomyelitis / chronic fatigue syndrome: neuropsycholo- gical symptoms and sex comparisons. J Transl Med 2018, 16:24.